Photoelectric Sensor Market

Diltiazem Market is projected to reach US$ 369.95 million by 2028 with CAGR of 12.3%

Diltiazem is used to treat high blood pressure and to control angina (chest pain). Diltiazem is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels, so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart.

Glenmark Pharmaceuticals and  Mylan N.V – Notable Market Players in Diltiazem Market

Market leaders operating in the market have undertaken various organic growth strategies in the Diltiazem market. The Diltiazem market majorly consists of the players Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag),Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, Zydus Pharmaceuticals among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.

Below is the list of the growth strategies done by the players operating in the Diltiazem market:

Year News
November 2020 Mylan N.V has completed its mergers with Upjohn and together formed Viatris,. Thus, Mylan NV has transformed into Viatris (Nasdaq: VTRS), the global drug manufacturer formed with the merger of Mylan and the Upjohn division of Pfizer Inc
March 2021 Glenmark Pharmaceuticals’ has received United States Food and Drug Administration (USFDA).Glenmark Pharmaceuticals has been granted a competitive generic therapy (CGT) designation for diltiazem hydrochloride extended release capsules USP, 60 mg, 90 mg, and 120 mg, therefore, with this approval,
March 2021 Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *